DE69916632D1 - Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind - Google Patents

Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind

Info

Publication number
DE69916632D1
DE69916632D1 DE69916632T DE69916632T DE69916632D1 DE 69916632 D1 DE69916632 D1 DE 69916632D1 DE 69916632 T DE69916632 T DE 69916632T DE 69916632 T DE69916632 T DE 69916632T DE 69916632 D1 DE69916632 D1 DE 69916632D1
Authority
DE
Germany
Prior art keywords
medicament
prevention
manufacture
treatment
acid derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69916632T
Other languages
English (en)
Other versions
DE69916632T2 (de
Inventor
Song Hae Bok
Tae Sook Jeong
Ki Hwan Bae
Yong Bok Park
Myung Sook Choi
Surk Sik Moon
Yong Kook Kwon
Eun Sook Lee
Byung Hwa Hyun
Yang Kyu Choi
Chul Ho Lee
Sae Bom Lee
Young Bae Park
Hyo Soo Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Application granted granted Critical
Publication of DE69916632D1 publication Critical patent/DE69916632D1/de
Publication of DE69916632T2 publication Critical patent/DE69916632T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/346Finished or semi-finished products in the form of powders, paste or liquids
    • AHUMAN NECESSITIES
    • A21BAKING; EDIBLE DOUGHS
    • A21DTREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14Organic oxygen compounds
    • A21D2/145Acids, anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/52Liquid products; Solid products in the form of powders, flakes or granules for making liquid products ; Finished or semi-finished solid products, frozen granules
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52Adding ingredients
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G2200/00COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DE69916632T 1998-09-15 1999-09-15 Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind Expired - Lifetime DE69916632T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19980037960 1998-09-15
PCT/KR1999/000551 WO2000015215A1 (en) 1998-09-15 1999-09-15 Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases

Publications (2)

Publication Number Publication Date
DE69916632D1 true DE69916632D1 (de) 2004-05-27
DE69916632T2 DE69916632T2 (de) 2005-04-21

Family

ID=19550603

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69916632T Expired - Lifetime DE69916632T2 (de) 1998-09-15 1999-09-15 Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind

Country Status (7)

Country Link
US (1) US6313171B1 (de)
EP (1) EP1113790B1 (de)
JP (1) JP2002524505A (de)
CN (1) CN1148176C (de)
CA (1) CA2344053C (de)
DE (1) DE69916632T2 (de)
WO (1) WO2000015215A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4119629B2 (ja) * 2001-09-06 2008-07-16 花王株式会社 高血圧症予防・改善・治療剤
WO2004016092A1 (en) * 2002-08-14 2004-02-26 Bionutrigen Co., Ltd Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them
EP1559421B1 (de) * 2002-11-06 2016-07-27 Kao Corporation Mittel zur förderung der blutzirkulation
KR100728055B1 (ko) * 2005-02-24 2007-06-13 (주)바이오뉴트리젠 비만증 및 고지혈증 예방용 식품
WO2007147075A2 (en) * 2006-06-16 2007-12-21 Applied Materials, Inc. Patterning 3d features in a substrate
FR2904935A1 (fr) * 2006-08-18 2008-02-22 Centre Nat Rech Scient Composition antidiabetique apte a stimuler la secretion d'insuline et destinee au traitement du diabete de type 2 (diabete non insulino-dependant).
WO2008099448A1 (ja) * 2007-02-09 2008-08-21 Masayoshi Yamaguchi 糖尿病性疾患の予防・治療剤
JP5417727B2 (ja) * 2007-03-28 2014-02-19 大正製薬株式会社 網膜保護剤
EP2409696B1 (de) * 2009-03-18 2018-06-27 Kao Corporation Mittel zur förderung des energieverbrauchs
FR2951085B1 (fr) * 2009-10-09 2012-05-18 Inst Substances Vegetales Utilisation de composes phenoliques pour la deglycation des proteines
AT509045B1 (de) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
MX370090B (es) 2013-02-01 2019-10-25 Centro De Investig En Alimentacion Y Desarrollo A C Un método y un sistema para el tratamiento integral de aguas residuales de una industria del maíz.
JP6051257B2 (ja) * 2015-04-15 2016-12-27 ライオン株式会社 脂質異常症への罹患しやすさを試験する方法
JP6708376B2 (ja) * 2015-07-10 2020-06-10 株式会社山田養蜂場本社 IFN−γ及び/又はIL−17の産生抑制剤、並びにTh1細胞及び/又はTh17細胞の分化抑制剤
WO2018227170A1 (en) * 2017-06-09 2018-12-13 Sheth Hetal Food compositions for mammals
CA3163526A1 (en) * 2019-12-05 2021-06-10 Flagship Pioneering Innovations V, Inc. Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2728971A (en) * 1970-04-13 1972-10-05 Sumitomo Chemical Company, Limited Production of cinnamic acid and its derivatives
US3707529A (en) * 1970-09-04 1972-12-26 Du Pont Elastomeric vinylidene fluoride polymers with 55-95 percent non-ionic end groups

Also Published As

Publication number Publication date
EP1113790B1 (de) 2004-04-21
JP2002524505A (ja) 2002-08-06
WO2000015215A1 (en) 2000-03-23
DE69916632T2 (de) 2005-04-21
CA2344053A1 (en) 2000-03-23
CN1148176C (zh) 2004-05-05
US6313171B1 (en) 2001-11-06
EP1113790A1 (de) 2001-07-11
CN1317961A (zh) 2001-10-17
CA2344053C (en) 2007-04-03

Similar Documents

Publication Publication Date Title
DE69916632D1 (de) Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DE3484055D1 (de) Verwendung von ubidecarenon zur herstellung eines medikaments zur behandlung von durch radiotherapie hervorgerufenen geschwueren.
DE69524679D1 (de) Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE60230425D1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE69934813D1 (de) Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen
DE60026152D1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
DE60029929D1 (de) VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
DE60220512D1 (de) Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE60128911D1 (de) Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen
DE60111574D1 (de) Bisphosphonate-enthaltenden zusammensetzungen zur vorbeugung und/oder heilung von metabolischen knochenkrankheiten, verfahren zu ihren herstellung und benutzung dieser zusammensetzungen
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE69632677D1 (de) Verwendung eines Rifamycin-Derivates zur Herstellung eines Medikamentes zur Behandlung von Krankheiten verursacht durch Helicobacter pylori-Infektionen
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE445394T1 (de) Verwendung von citrullin zur herstellung eines arzneimittels zur behandlung von ans altern oder an eine bestrahlung gebundener intestinaler insuffizienz
DE69915848D1 (de) Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte
DE69428797D1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition